About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 389046, 10 pages
http://dx.doi.org/10.1155/2013/389046
Research Article

Effect of Folic Acid and Vitamin on Pemetrexed Antifolate Chemotherapy in Nutrient Lung Cancer Cells

1Institute of Medicine, Chung Shan Medical University, No. 110, Sec 1, Jianguo N. Road, Taichung 402, Taiwan
2Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, No. 160, Sec 3, Chung-Kang, Taichung 407, Taiwan
3Department of Medicine, School of Medicine, National Yang-Ming University, 155, Sec 2, Lih-Non Street, Shih-Pai 112, Taipei, Taiwan
4Institute of Biomedical Sciences, National Chung Hsing University, No. 160, Sec 3, Chung-Kang, Taichung 407, Taiwan
5Department of Education and Research, Taichung Veterans General Hospital, No. 160, Sec 3, Chung-Kang, Taichung 407, Taiwan
6Department of Medical Oncology and Chest Medicine, Chung Shan Medical University Hospital, No. 110, Sec 1, Jianguo N. Road, Taichung 402, Taiwan

Received 23 April 2013; Accepted 8 July 2013

Academic Editor: Ruxana T. Sadikot

Copyright © 2013 Tsung-Ying Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Ciuleanu, T. Brodowicz, C. Zielinski et al., “Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study,” The Lancet, vol. 374, no. 9699, pp. 1432–1440, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Vlastos, G. Hillas, P. Vidal et al., “Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: the nancy centre of biological resources- mesothelioma cohort,” Journal of Thoracic Oncology, vol. 4, no. 10, pp. 1259–1263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Pippen, A. Elias, M. Neubauer et al., “A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy,” Clinical Breast Cancer, vol. 10, no. 2, pp. 148–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Underhill, D. Goldstein, V. A. Gorbounova et al., “A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer,” Oncology, vol. 73, no. 1-2, pp. 9–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. R. V. Iaffaioli, A. Milano, and F. Caponigro, “Therapy of metastatic bladder carcinoma,” Annals of Oncology, vol. 18, no. 6, pp. vi153–vi156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Lorusso, G. Ferrandina, S. Pignata et al., “Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group,” Annals of Oncology, vol. 21, no. 1, pp. 61–66, 2010. View at Scopus
  7. L. Celio, C. N. Sternberg, R. Labianca et al., “Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study,” Annals of Oncology, vol. 20, no. 6, pp. 1062–1067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Mercalli, V. Sordi, R. Formicola et al., “A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer,” British Journal of Cancer, vol. 96, no. 9, pp. 1358–1367, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Respaud, J.-F. Tournamille, C. Croix, H. Laborie, C. Elfakir, and M.-C. Viaud-Massuard, “Development of an ion-pairing reversed-phase liquid chromatography method using a double detection analysis (UV and evaporative light scattering detection) to monitor the stability of Alimta-pemetrexed preparations: identification and quantification of l-glutamic acid as a potential degradation product,” Journal of Pharmaceutical and Biomedical Analysis, vol. 54, no. 2, pp. 411–416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Shih, L. L. Habeck, L. G. Mendelsohn, V. J. Chen, and R. M. Schultz, “Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA),” Advances in Enzyme Regulation, vol. 38, no. 1, pp. 135–152, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. I. D. Goldman and R. Zhao, “Molecular, biochemical, and cellular pharmacology of pemetrexed,” Seminars in Oncology, vol. 29, no. 6, pp. 3–17, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Niyikiza, S. D. Baker, D. E. Seitz et al., “Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy,” Molecular cancer therapeutics, vol. 1, no. 7, pp. 545–552, 2002. View at Scopus
  13. N. J. Vogelzang, J. J. Rusthoven, J. Symanowski et al., “Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2636–2644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Joerger, A. Omlin, T. Cerny, and M. Früh, “The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action,” Current Drug Targets, vol. 11, no. 1, pp. 37–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. B. Gates, J. F. Worzalla, C. Shih, G. B. Grindey, and L. G. Mendelsohn, “Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts,” Biochemical Pharmacology, vol. 52, no. 9, pp. 1477–1479, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Farber and L. K. Diamond, “Temporary remissions in acute leukemia in children produced by folic,” The New England Journal of Medicine, vol. 238, no. 23, pp. 787–793, 1948. View at Scopus
  17. Y. G. Assaraf, “Molecular basis of antifolate resistance,” Cancer and Metastasis Reviews, vol. 26, no. 1, pp. 153–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Zhao, F. Gao, and I. D. Goldman, “Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells,” Biochemical Pharmacology, vol. 61, no. 7, pp. 857–865, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. G. V. Scagliotti, D.-M. Shin, H. L. Kindler et al., “Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma,” Journal of Clinical Oncology, vol. 21, no. 8, pp. 1556–1561, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. B. A. Teicher, V. Chen, C. Shih et al., “Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts,” Clinical Cancer Research, vol. 6, no. 3, pp. 1016–1023, 2000. View at Scopus
  21. J. L. Tonkinson, J. F. Worzalla, C.-H. Teng, and L. G. Mendelsohn, “Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma,” Cancer Research, vol. 59, no. 15, pp. 3671–3676, 1999. View at Scopus
  22. D. L. Scott, F. Wolfe, and T. W. J. Huizinga, “Rheumatoid arthritis,” The Lancet, vol. 376, no. 9746, pp. 1094–1108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. B. C. Widemann and P. C. Adamson, “Understanding and managing methotrexate nephrotoxicity,” Oncologist, vol. 11, no. 6, pp. 694–703, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. D. Smith, Y.-I. Kim, and H. Refsum, “Is folic acid good for everyone?” American Journal of Clinical Nutrition, vol. 87, no. 3, pp. 517–533, 2008. View at Scopus
  25. J. E. Baggott and S. L. Morgan, “Folic acid supplements are good (not bad) for rheumatoid arthritis patients treated with lowdose methotrexate,” American Journal of Clinical Nutrition, vol. 88, no. 2, pp. 479–480, 2008. View at Scopus
  26. M.-F. Wu, Y.-M. Hsiao, C.-F. Huang et al., “Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells,” Journal of Thoracic Oncology, vol. 5, no. 8, pp. 1143–1151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. J. Welsh, J. Titley, L. Brunton et al., “Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues,” Clinical Cancer Research, vol. 6, no. 6, pp. 2538–2546, 2000. View at Scopus
  28. J. I. Geller, K. Szekely-Szucs, I. Petak, B. Doyle, and J. A. Houghton, “p21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells,” Cancer Research, vol. 64, no. 17, pp. 6296–6303, 2004. View at Publisher · View at Google Scholar · View at Scopus